Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization

• DOI: 10.1016/j.jhepr.2023.100995
• Publication Date: 2023-12-27T02:50:17Z
• Authors: Osman Öcal; Melanie Alexandra...; Thi Phuong Thao H...; Maciej Pech; Elif Öcal; Najib Ben Khaled; Bruno Sangro; Jens Ricke; Max Seidensticker; Moritz Wildgruber
• Keywords: Post-hoc analysis

Background & AimsTo explore the predictive value of systemic inflammatory markers (neutrophil-to-lymphocyte ratio [NLR] and platelet-to-lymphocyte [PLR]) in patients with advanced HCC treated sorafenib monotherapy or selective internal radiation therapy (SIRT)/sorafenib combination.MethodsPatients randomized to SIRT/sorafenib within per-protocol population SORAMIC trial were evaluated this exploratory post-hoc analysis. The median baseline NLR PLR used as cut-off values describe subgroups. Kaplan-Meier curves log-rank tests evaluate survival arms each subgroup. Multivariable Cox regression analysis was applied eliminate effect confounding factors.ResultsA total 274 a overall 12.4 months included cohort 2.77, 26.5. There no significant difference low (p=0.72) (p=0.35) values. In high values, there statistically between cohorts (12.1 vs. 9.2 months, p=0.21). arm significantly longer than (15.9 11.0 p=0.029). This preserved multivariable (SIRT/sorafenib HR 0.65 [0.44-0.96], p=0.03) incorporating age, Child-Pugh grade, alpha-fetoprotein levels.ConclusionsPLR is potential factor benefit from additional SIRT receiving therapy. Potential should be further future trials.Impact implicationsSystemic therapies are mainstay treatment hepatocellular carcinoma at stages. However, not all respond well these treatments. our analysis, using blood test parameters showing inflammation status, we able identify who would more combined locoregional radioembolization (or therapy).